mdma
Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology (Wittenkeller, et al, 2025)
"enhancing baseline dopamine while minimising excessive drug-induced dopamine surges may help normalise motivational circuits and reduce relapse risk."
lsd
Spotlight: Single Treatment With MM120 (Lysergide) in Generalized Anxiety DisorderA Randomized Clinical Trial (Robinson, et al, 2025)
In this phase 2b, multicenter, randomized, double-blind, placebo-controlled study of 4 dose levels of MM120 (a form of LSD) that included 198 adults with generalized anxiety disorder 4 was statistically significant.
psychedelic research
Spotlight: Deconstructing the trip treatment: are hallucinogenic effects critical to the therapeutic benefits of psychedelics? (Garcia-Romeu, 2025)
The relative contribution of drug vs. psychological support remains to be determined, though preliminary data indicate the therapeutic relationship can impact treatment outcomes [12], and factors such as environment, personality, and mindset can influence subjective drug effects.
ketamine therapy telehealth
HHS Releases Telehealth Guide
Learn how to get the best results with telehealth
psychedelics
The Neuroscience of Ketamine / Psychedelics and Meditation Experiences
Neural correlates and subjective experiences in meditation, psychedelic medicines including ketamine: A preliminary, evolving review of the literature. (2026 updates)
cbt
Cognitive Behavioral Ketamine Psychedelic Therapy
Cognitive Behavioral & Psychedelic Ketamine Therapy in the Research
psychedelic therapy
Psychedelic Cognitive Behavioral Therapy (Preliminary Lit Review)
An evolving overview of cognitive behavioral therapy in psychedelic-assisted psychotherapy and ketamine psychedelic therapy.
